AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 32885188
Drug: BetterBirth intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: BetterBirth intervention implementing the WHO Safe Childbirth Checklist; details on dosage and duration not available.
Trial: 32885188
Drug: BetterBirth intervention;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BetterBirth intervention; details on dosage and duration not available.
Trial: 32885198
Drug: Positive-Minds-Strong Bodies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Positive-Minds-Strong Bodies (PM-SB) intervention consisting of cognitive behavior therapy and exercise training sessions delivered over 6 months.
Trial: 32885217
Drug: High scores
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High scores on CFIR organizational characteristics (e.g., organizational readiness, implementation climate, organizational culture, innovation fit)
Trial: 32886347
Drug: Imipenem 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imipenem 0.5 g every 6 hours
Trial: 32886347
Drug: Imipenem 1
RxNorm normalized name: IMIPENEM 1 kg in 1 kg NOT APPLICABLE POWDER [Imipenem]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imipenem 1 g every 6 hours
Trial: 32886753
Drug: Rozanolixizumab (15-21
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rozanolixizumab (15-21 mg/kg cumulative doses, administered as 1 to 5 once-weekly subcutaneous infusions)
Trial: 32886753
Drug: Rozanolixizumab (15-20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rozanolixizumab (15-20 mg/kg single doses)
Trial: 32886914
Drug: Procalcitonin (PCT)
RxNorm normalized name: Procalcitonin
DrugBank: Procalcitonin (DB14812)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Procalcitonin (PCT) levels measured daily in the first 3 days post-aSAH
Trial: 32887722
Drug: Ribociclib 600
RxNorm normalized name: letrozole 2.5 MG / ribociclib 600 MG Daily Dose Carton
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ribociclib 600 mg (3 weeks on, 1 week off) plus Fulvestrant 500 mg
Trial: 32887722
Drug: Ribociclib 400
RxNorm normalized name: ribociclib 400 MG / letrozole 2.5 MG Daily Dose Carton
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ribociclib 400 mg plus Buparlisib 30 mg plus Fulvestrant 500 mg
Trial: 32887722
Drug: Ribociclib 400
RxNorm normalized name: ribociclib 400 MG / letrozole 2.5 MG Daily Dose Carton
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ribociclib 400 mg plus Alpelisib (no RP2D determined)
Trial: 32888036
Drug: Serum BMP-7
RxNorm normalized name: BMP-7
DrugBank: Eptotermin alfa (DB11631)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Serum BMP-7 with TNF inhibitor (TNFi) use
Trial: 32888723
Drug: Long-acting reversible
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long-acting reversible contraceptive methods (intrauterine device and contraceptive implant)
Trial: 32889146
Drug: AFP ≥7.32
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AFP ≥7.32 ng/mL
Trial: 32890324
Drug: Contrast-enhanced ultrasound
RxNorm normalized name: Contrased
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Contrast-enhanced ultrasound (CEUS) performed 2 weeks after initial TACE treatment.
Trial: 32891132
Drug: Long-term androgen
RxNorm normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Long-term androgen treatment
Trial: 32891400
Drug: Thrombocytopenia (platelet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thrombocytopenia (platelet count <150 × 10^9/L)
Trial: 32891400
Drug: Normal platelet
RxNorm normalized name: platelet glycoprotein VI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal platelet count (≥150 × 10^9/L)
Trial: 32891715
Drug: Trifluridine/tipiracil (FTD/TPI)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trifluridine/tipiracil (FTD/TPI) treatment prior to irradiation for 24 hours
Trial: 32891715
Drug: Combined in
RxNorm normalized name: POISON IVY/OAK/SUMAC EXTRACTS COMBINED INJ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined in vivo treatment with FTD/TPI and radiation
Trial: 32893393
Drug: 3 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 mg/kg dupilumab
Trial: 32893393
Drug: 6 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 mg/kg dupilumab
Trial: 32893393
Drug: dupilumab (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: dupilumab (both doses)
Trial: 32894185
Drug: CNCT19 CAR
RxNorm normalized name: Anti-BCMA CAR T cell
DrugBank: Idecabtagene vicleucel (DB16665)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CNCT19 CAR T therapy
Trial: 32894672
Drug: Thiol supplements
RxNorm normalized name: 1-p-menthene-8-thiol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thiol supplements
Trial: 32894868
Drug: Volatile organic
RxNorm normalized name: coal tar pitch volatiles
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Volatile organic compounds (VOCs) in bile
Trial: 32897236
Drug: Biannual topical
RxNorm normalized name: annual bluegrass pollen extract
DrugBank: Poa annua pollen (DB10353)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biannual topical application of silver diamine fluoride
Trial: 32897236
Drug: Atraumatic restorative
RxNorm normalized name: DRESSING,RESTORE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atraumatic restorative treatment + biannual fluoride varnish
Trial: 32900761
Drug: Changes in
RxNorm normalized name: guaifenesin / hydrocodone bitartrate Oral Solution [Canges XP]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Changes in medication purchases (painkillers and indigestion medication) 10-12 months before ovarian cancer diagnosis
Trial: 32901324
Drug: Serum lipase
RxNorm normalized name: lipase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serum lipase > 51 U/L on POD3
Trial: 32901324
Drug: IL-6 >
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IL-6 > 56.5 ng/l on POD3
Trial: 32901324
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of serum lipase and IL-6 on POD3
Trial: 32902099
Drug: Oral Anticoagulation
RxNorm normalized name: monitoring agent for oral anticoagulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Anticoagulation Therapy (OAT)
Trial: 32903035
Drug: Radiopharmaceutical administrations
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Radiopharmaceutical administrations during diagnostic nuclear medicine procedures
Trial: 32903035
Drug: Detailed analysis
RxNorm normalized name: Chemicals and reagents for analysis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Detailed analysis of radiation dose calculations
Trial: 32903199
Drug: Convalescent Plasma
RxNorm normalized name: Convalescent plasma
DrugBank: COVID-19 convalescent plasma (DB15692)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Convalescent Plasma (CP) infusion
Trial: 32903267
Drug: Karate intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Karate intervention (10-week, twice weekly classes)
Trial: 32903394
Drug: Dance Movement
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dance Movement Therapy (DMT) + Treatment as Usual (TAU)
Trial: 32903594
Drug: First-Line Treatment
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: First-Line Treatment
Trial: 32903623
Drug: Personalized medicine
RxNorm normalized name: Medicaine Sting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Personalized medicine intervention
Trial: 32904162
Drug: Rosuvastatin 10
RxNorm normalized name: rosuvastatin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosuvastatin 10 mg + Ezetimibe 10 mg (R/E)
Trial: 32904162
Drug: Simvastatin 20
RxNorm normalized name: simvastatin 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simvastatin 20 mg + Ezetimibe 10 mg (S/E)
Trial: 32904162
Drug: Rosuvastatin 20
RxNorm normalized name: rosuvastatin 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosuvastatin 20 mg + Ezetimibe 10 mg (R/E)
Trial: 32904162
Drug: Simvastatin 40
RxNorm normalized name: simvastatin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simvastatin 40 mg + Ezetimibe 10 mg (S/E)
Trial: 32905674
Drug: Recombinant factor
RxNorm normalized name: Recombinant factor IX
DrugBank: Coagulation Factor IX (Recombinant) (DB00100)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant factor VIII at a dose of 25 IU/kg
Trial: 32905674
Drug: Recombinant factor
RxNorm normalized name: Recombinant factor IX
DrugBank: Coagulation Factor IX (Recombinant) (DB00100)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant factor VIII at a dose of 65 IU/kg
Trial: 32905674
Drug: BIVV001 at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BIVV001 at a dose of 65 IU/kg
Trial: 32907357
Drug: Hydroxychloroquine 400
RxNorm normalized name: hydroxychloroquine 400 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydroxychloroquine 400 mg daily during pregnancy
Trial: 32907766
Drug: Mindfulness therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mindfulness therapy applied to experimental group patients
Trial: 32907766
Drug: Mindfulness therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mindfulness therapy (experimental group)
Trial: 32907782
Drug: Sacral neuromodulation
RxNorm normalized name: Boswellia sacra whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sacral neuromodulation (SNM) therapy with the InterStim™ system
Trial: 32907899
Drug: Individual-level factors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individual-level factors (e.g., walking distance to health facility, ANC visits, last birth at health facility, number of children, knowledge on FP, intentions to use FP)
Trial: 32907899
Drug: Community-level factors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Community-level factors (e.g., electronic media possession, women's decision making on FP)
Trial: 32908559
Drug: Ultrasound-guided percutaneous
RxNorm normalized name: ULTRASOUND
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrasound-guided percutaneous needle electrolysis (PNE) in combination with an eccentric exercise program
Trial: 38330045
Drug: Same-day initiation
RxNorm normalized name: SAMe
DrugBank: Ademetionine (DB00118)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Same-day initiation (SDI) of antiretroviral therapy (ART)
Trial: 32910099
Drug: High-dose spinal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose spinal cord stimulation (HD-SCS)
Trial: 32910151
Drug: Doxorubicin plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxorubicin plus pembrolizumab (45 and 75 mg/m2)
Trial: 32910776
Drug: rs738409(G) SNP
RxNorm normalized name: SNP-ACTH (1-39)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rs738409(G) SNP variant
Trial: 32912180
Drug: Melatonin 1,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Melatonin 1, 2, or 4 mg granules orally
Trial: 32912664
Drug: Weekly paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Weekly paclitaxel (WP) monotherapy
Trial: 32913286
Drug: sapanisertib 5
RxNorm normalized name: SAPANISERTIB
DrugBank: Sapanisertib (DB11836)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sapanisertib 5 mg QD
Trial: 32913286
Drug: sapanisertib 40
RxNorm normalized name: SAPANISERTIB
DrugBank: Sapanisertib (DB11836)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sapanisertib 40 mg QW
Trial: 32913286
Drug: sapanisertib 30
RxNorm normalized name: SAPANISERTIB
DrugBank: Sapanisertib (DB11836)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sapanisertib 30 mg QW
Trial: 32913985
Drug: RNA-seq classifiers
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RNA-seq classifiers for hormone responsiveness
Trial: 32913985
Drug: MGC hormone-responsive
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: MGC hormone-responsive classifier
Trial: 32914038
Drug: Experimental arms
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Experimental arms of innovative glioblastoma therapy
Trial: 32914038
Drug: Standard concurrent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard concurrent temozolomide and radiation therapy followed by adjuvant temozolomide (Control)
Trial: 32914172
Drug: Levonorgestrel-releasing intravaginal
RxNorm normalized name: Levonorgestrel
DrugBank: Levonorgestrel (DB00367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Levonorgestrel-releasing intravaginal ring (IVR) delivering 40 µg LNG per day
Trial: 32914187
Drug: BDG concentration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BDG concentration >100 pg/mL
Trial: 32914187
Drug: Multiple (≥2)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple (≥2) positive results >100 pg/mL or a BDG concentration increasing >100 pg/mL
Trial: 32914187
Drug: BDG concentration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BDG concentration >100 pg/mL in patients with IC
Trial: 32914187
Drug: BDG concentration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BDG concentration ≤100 pg/mL in patients with IC
Trial: 32914187
Drug: BDG concentration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BDG concentration >100 pg/mL in patients without IC
Trial: 32914581
Drug: Desmopressin 25-μg
RxNorm normalized name: desmopressin
DrugBank: Desmopressin (DB00035)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Desmopressin 25-μg ODTs
Trial: 32914581
Drug: Desmopressin 50-μg
RxNorm normalized name: desmopressin
DrugBank: Desmopressin (DB00035)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Desmopressin 50-μg ODTs
Trial: 32914581
Drug: Desmopressin ODTs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Desmopressin ODTs (25 and 50 μg)
Trial: 32915384
Drug: Daratumumab subcutaneous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daratumumab subcutaneous (DARA SC) 1,800 mg
Trial: 32915419
Drug: Crenigacestat (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Crenigacestat (75 mg escalating to 150 mg TIW for 2 weeks, then 50 mg TIW) + Prednisone (co-administered for 2 weeks in Cycle 1)
Trial: 32915419
Drug: Crenigacestat (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Crenigacestat (75 mg TIW)
Trial: 32915419
Drug: Crenigacestat (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Crenigacestat (100 mg BIW)
Trial: 32915679
Drug: CaboNivo (cabozantinib
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CaboNivo (cabozantinib 40 mg/d plus nivolumab 3 mg/kg)
Trial: 32915679
Drug: CaboNivoIpi (cabozantinib
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CaboNivoIpi (cabozantinib 40 mg/d, nivolumab 3 mg/kg, and ipilimumab 1 mg/kg)
Trial: 32916296
Drug: Tiotropium +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tiotropium + Olodaterol fixed-dose combination (5 μg/5 μg)
Trial: 32916310
Drug: Almonertinib (HS-10296)
RxNorm normalized name: Almonertinib
DrugBank: Almonertinib (DB16640)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Almonertinib (HS-10296) at doses of 55, 110, 220 mg
Trial: 38171926
Drug: Liver-directed gene
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liver-directed gene therapy
Trial: 32917192
Drug: 37.5% hydrogen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 37.5% hydrogen peroxide gel
Trial: 32917626
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of elevated serum ACE and lymphopaenia
Trial: 32917626
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of elevated serum ACE and lymphopaenia in patients aged ≤50 years
Trial: 32917626
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of elevated serum ACE and lymphopaenia in granulomatous uveitis
Trial: 32918045
Drug: SAF-189s, a
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SAF-189s, a new-generation ROS1/ALK inhibitor
Trial: 32918045
Drug: Crizotinib (first-generation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Crizotinib (first-generation ROS1 inhibitor)
Trial: 32919178
Drug: apixaban 10
RxNorm normalized name: Apixaban
DrugBank: Apixaban (DB06605)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: apixaban 10 mg bid for seven days, then 5 mg bid for six months
Trial: 32919458
Drug: Discordant therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Discordant therapy
Trial: 32919527
Drug: Intramuscular extended-dose
RxNorm normalized name: intramuscular immunoglobulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular extended-dose fulvestrant 500 mg (Cohort A)
Trial: 32919527
Drug: Oral neratinib
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral neratinib 240 mg and intramuscular standard-dose fulvestrant (Cohort B)
Trial: 32919527
Drug: Oral capivasertib
RxNorm normalized name: Capivasertib
DrugBank: Capivasertib (DB12218)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral capivasertib 400 mg plus intramuscular standard-dose fulvestrant (Cohort C)
Trial: 32919527
Drug: Oral capivasertib
RxNorm normalized name: Capivasertib
DrugBank: Capivasertib (DB12218)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral capivasertib 480 mg (Cohort D)
Trial: 32920453
Drug: Epworth Sleepiness
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epworth Sleepiness Scale (ESS) after PAP therapy
Trial: 32920652
Drug: Residual drug
RxNorm normalized name: antihemophilic factor, human recombinant residues 743-1636 deleted Injection [Xyntha]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Residual drug level (RDL) feedback from counselors
Trial: 32921507
Drug: Pentacel vaccine
RxNorm normalized name: PENTACEL VACCINE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pentacel vaccine (Group 1)
Trial: 32921507
Drug: Other brand
RxNorm normalized name: Eagle Brand Medicated Oil
DrugBank: Eucalyptus oil (DB11114)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Other brand of vaccine (Group 2)
Trial: 32922454
Drug: Electronic monitoring
RxNorm normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electronic monitoring combined with IMS-based weekly feedback and reminders
Trial: 32922827
Drug: Renal denervation
RxNorm normalized name: Sus scrofa renal pelvis preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Renal denervation (treatment group)
Trial: 32923156
Drug: TIL therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TIL therapy alone
Trial: 32923156
Drug: Cyclophosphamide/fludarabine preconditioning
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclophosphamide/fludarabine preconditioning and intravenous IL-2 after TIL transfer
Trial: 32923156
Drug: DC vaccine
RxNorm normalized name: Recombinant chimeric COVID-19 DC vaccine
DrugBank: Dendritic cells vaccine (DB15803)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DC vaccine (five intradermal injections)
Trial: 32923921
Drug: LA-rich vegetable
RxNorm normalized name: Hydrogenated Vegetable Oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LA-rich vegetable oil (10 mL/d)
Trial: 32924093
Drug: SM-88 (230
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SM-88 (230 mg BID), methoxsalen (10 mg), phenytoin (50 mg), sirolimus (0.5 mg)
Trial: 32924568
Drug: Fast-Acting Insulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fast-Acting Insulin Aspart
Trial: 32925563
Drug: Autologous dendritic
RxNorm normalized name: COVID19 s-vax loaded autologous dendritic cell vaccine
DrugBank: COVID19 s-vax loaded autologous dendritic cell vaccine (DB15814)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Autologous dendritic cells transduced with AdGMCA9 (DC-AdGMCAIX) injected intradermally at doses of 5, 15, and 50×10 cells/administration, every 2 weeks for 3 doses.
Trial: 32927016
Drug: 500 mL
RxNorm normalized name: TPN Bag 500 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mL of orange juice (OJ)
Trial: 32928136
Drug: Salvage chemoradiation
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Salvage chemoradiation therapy (CRT)
Trial: 32928264
Drug: Endocrine therapy
RxNorm normalized name: ENDOCRINE THERAPY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endocrine therapy and palbociclib
Trial: 32928517
Drug: Epinephrine administration
RxNorm normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Epinephrine administration before ICU admission
Trial: 32928701
Drug: 1-hour glucose
RxNorm normalized name: glucose 1 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1-hour glucose (1hG) ≥155 mg/dL
Trial: 32928795
Drug: Pomalidomide, low-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pomalidomide, low-dose dexamethasone (LoDEX), and daratumumab
Trial: 32928796
Drug: Flumatinib 600
RxNorm normalized name: Flumatinib
DrugBank: Flumatinib (DB11904)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flumatinib 600 mg once daily
Trial: 32928858
Drug: Tenofovir disoproxil
RxNorm normalized name: Tenofovir Disoproxil
DrugBank: Tenofovir disoproxil (DB00300)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tenofovir disoproxil fumarate (TDF) treatment initiated prior to 20 weeks gestation, cessation of TDF 1 month after delivery.
Trial: 32928858
Drug: Monitoring of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monitoring of adverse events including risk of flare and adherence based on pill count and questionnaire.